Comparing Aptinyx (APTX) and Catalent (CTLT)

Aptinyx (NASDAQ:APTX) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Aptinyx and Catalent, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptinyx 0 0 4 0 3.00
Catalent 0 3 8 0 2.73

Aptinyx presently has a consensus target price of $32.33, indicating a potential upside of 12.62%. Catalent has a consensus target price of $49.71, indicating a potential upside of 9.74%. Given Aptinyx’s stronger consensus rating and higher probable upside, analysts clearly believe Aptinyx is more favorable than Catalent.

Insider & Institutional Ownership

60.1% of Aptinyx shares are held by institutional investors. Comparatively, 92.0% of Catalent shares are held by institutional investors. 1.7% of Catalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


This table compares Aptinyx and Catalent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aptinyx N/A N/A N/A
Catalent 3.39% 20.42% 4.97%

Valuation and Earnings

This table compares Aptinyx and Catalent’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptinyx $4.96 million 193.91 -$32.06 million N/A N/A
Catalent $2.46 billion 2.67 $83.60 million $1.59 28.49

Catalent has higher revenue and earnings than Aptinyx.


Catalent beats Aptinyx on 8 of the 11 factors compared between the two stocks.

Aptinyx Company Profile

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Catalent Company Profile

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with's FREE daily email newsletter.

Leave a Reply